Get the Stockscreener App
106.82
9.90%
9.62
After Hours:
106.00
-0.82
-0.77%
Nuvalent Inc stock is traded at $106.82, with a volume of 895.69K.
It is up +9.90% in the last 24 hours and down -2.54% over the past month.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
See More
Previous Close:
$97.20
Open:
$97.88
24h Volume:
895.69K
Relative Volume:
1.47
Market Cap:
$8.30B
Revenue:
-
Net Income/Loss:
$-224.29M
P/E Ratio:
-27.39
EPS:
-3.9
Net Cash Flow:
$-185.06M
1W Performance:
+6.19%
1M Performance:
-2.54%
6M Performance:
+37.07%
1Y Performance:
+33.33%
1-Day Range:
$97.64
$108.46
1-Week Range:
$95.50
$108.46
52-Week Range:
$55.53
$112.88
Nuvalent Inc Stock (NUVL) Company Profile
Name
Nuvalent Inc
Sector
Industry
Phone
508-446-2272
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Compare NUVL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NUVL
Nuvalent Inc
|
106.82 | 7.55B | 0 | -224.29M | -185.06M | -3.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Nuvalent Inc Stock (NUVL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Nov-12-25 | Initiated | Canaccord Genuity | Buy |
| Oct-16-25 | Resumed | Stifel | Buy |
| Oct-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-04-25 | Resumed | Guggenheim | Buy |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Mar-14-25 | Upgrade | UBS | Neutral → Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Oct-24-24 | Initiated | UBS | Neutral |
| Aug-29-24 | Initiated | Barclays | Overweight |
| Apr-17-24 | Initiated | Jefferies | Buy |
| Apr-01-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-28-24 | Resumed | Guggenheim | Buy |
| Feb-23-24 | Initiated | Robert W. Baird | Outperform |
| Sep-27-23 | Initiated | Stifel | Buy |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-24-23 | Initiated | Guggenheim | Buy |
| Jan-18-23 | Initiated | Wedbush | Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
View All
Nuvalent Inc Stock (NUVL) Latest News
Will Nuvalent’s Momentum Continue? - StocksToTrade
Avoiding Lag: Real-Time Signals in (NUVL) Movement - Stock Traders Daily
Bear Alert: How Nuvalent Inc stock performs in weak economyWeekly Stock Analysis & Daily Profit Maximizing Tips - moha.gov.vn
Nuvalent, Inc. (NASDAQ:NUVL) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
What's Going On With Royalty Pharma Stock Wednesday? - Benzinga
PRN_FinancialWrapper | PR NewswireNuvalent, Inc.Class A Common Stock (Nasdaq:NUVL) Stock Quote - FinancialContent
Nuvalent Earnings Notes - Trefis
Towards 2026, Focusing on Three High-Potential Biotechnology Companies - NAI500
Nuvalent’s royalty interest acquired by Royalty Pharma - MSN
3 Biotech Stocks With Major 2026 Catalysts - Nasdaq
Truist Securities Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation - MSN
Nuvalent (NUVL): Assessing an Expensive-Looking Valuation After a Strong Multi-Year Share Price Run - Yahoo Finance
Nuvalent, Inc. $NUVL Shares Bought by Voya Investment Management LLC - MarketBeat
Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference - Sahm
Nuvalent files for mixed shelf offering size not disclosedSEC filing - marketscreener.com
Technical Reactions to NUVL Trends in Macro Strategies - Stock Traders Daily
What drives Nuvalent Inc stock priceStock Buyback Updates & Follow Top Performers in the Community - earlytimes.in
Why Nuvalent Inc. stock remains a top recommendationJuly 2025 WrapUp & High Accuracy Swing Trade Signals - Улправда
Can Nuvalent Inc. stock reach $100 price target2025 Big Picture & Proven Capital Preservation Methods - Улправда
JPMorgan Chase & Co. Lowers Nuvalent (NASDAQ:NUVL) Price Target to $145.00 - MarketBeat
Aug Sentiment: Is Nuvalent Inc. stock a defensive play in 2025Weekly Loss Report & Community Trade Idea Sharing Platform - DonanımHaber
Is Nuvalent Inc. stock a defensive play in 20252025 Key Lessons & Daily Stock Momentum Reports - DonanımHaber
JP Morgan Lowers Target Price for Nuvalent (NUVL) to $145 | NUVL Stock News - GuruFocus
Certain Restricted Stock Units of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Certain Options of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
66,836,884 Common Stock of Nuvalent, Inc. are subject to a Lock-Up Agreement Ending on 19-DEC-2025. - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN) - The Globe and Mail
Barclays Reaffirms Their Buy Rating on Nuvalent (NUVL) - The Globe and Mail
UBS reiterates Buy rating on Nuvalent stock, citing Royalty Pharma deal - Investing.com Canada
[8-K] Nuvalent, Inc. Reports Material Event | NUVL SEC FilingForm 8-K - Stock Titan
Nuvalent’s Royalty Interest Acquired by Royalty Pharma - The Globe and Mail
Nuvalent Acknowledges Royalty Pharma's Acquisition of Royalty Interest - TradingView — Track All Markets
Royalty Pharma Acquires Royalty Interest in Nuvalent's Potential Lung Cancer Therapies - marketscreener.com
Royalty Pharma acquires royalty interest in Nuvalent's neladalkib and zidesamtinib for up to $315 million - marketscreener.com
Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million - Quiver Quantitative
Royalty Pharma Acquires Royalty Interest in Nuvalent’s Neladalkib and Zidesamtinib for Up to $315 Million - marketscreener.com
Royalty Pharma (Nasdaq: RPRX) buys Nuvalent NSCLC royalties for up to $315M - Stock Titan
Nuvalent announces public offering of common stock - MSN
Nuvalent, Inc. $NUVL Shares Acquired by Braidwell LP - MarketBeat
Is Nuvalent Inc stock a defensive play in 2025Trade Analysis Summary & Expert Curated Trade Setup Alerts - moha.gov.vn
Natixis Makes New $1.75 Million Investment in Nuvalent, Inc. $NUVL - MarketBeat
Insider Selling: Nuvalent (NASDAQ:NUVL) CFO Sells 7,084 Shares of Stock - MarketBeat
Nuvalent (NUVL) director discloses RSU and stock option acquisitions - Stock Titan
Nuvalent, Inc. (NUVL) is a buy on lung cancer treatment prospects - MSN
HighVista Strategies LLC Has $3.85 Million Stake in Nuvalent, Inc. $NUVL - MarketBeat
Nuvalent appoints Ron Squarer to board of directors By Investing.com - Investing.com Nigeria
Ron Squarer Joins Nuvalent Board as Independent Director - The Globe and Mail
Trading the Move, Not the Narrative: (NUVL) Edition - news.stocktradersdaily.com
Insider Sell Alert: Alexandra Balcom Sells Shares of Nuvalent In - GuruFocus
Nuvalent Appoints Ron Squarer to Board of Directors - GuruFocus
Nuvalent Inc Stock (NUVL) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):